company background image
ALC

Alcidion GroupASX:ALC Stock Report

Market Cap

AU$366.8m

7D

-1.4%

1Y

180.0%

Updated

15 Oct, 2021

Data

Company Financials +
ALC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ALC Overview

Alcidion Group Limited, together with its subsidiaries, engages in the development and licensing of healthcare software products in Australia, New Zealand, and the United Kingdom.

Price History & Performance

Summary of all time highs, changes and price drops for Alcidion Group
Historical stock prices
Current Share PriceAU$0.35
52 Week HighAU$0.12
52 Week LowAU$0.48
Beta0.89
1 Month Change-9.09%
3 Month Change-6.67%
1 Year Change180.00%
3 Year Change660.87%
5 Year Change392.96%
Change since IPO438.46%

Recent News & Updates

Shareholder Returns

ALCAU Healthcare ServicesAU Market
7D-1.4%-0.3%0.1%
1Y180.0%45.9%19.3%

Return vs Industry: ALC exceeded the Australian Healthcare Services industry which returned 45.9% over the past year.

Return vs Market: ALC exceeded the Australian Market which returned 19.3% over the past year.

Price Volatility

Is ALC's price volatile compared to industry and market?
ALC volatility
ALC Beta0.89
Industry Beta0.49
Market Beta1

Stable Share Price: ALC is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: ALC's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2000n/aKate Quirkehttps://www.alcidion.com

Alcidion Group Limited, together with its subsidiaries, engages in the development and licensing of healthcare software products in Australia, New Zealand, and the United Kingdom. The company offers Miya Precision, a consolidated fast healthcare interoperability resource (FHIR) based platform to deliver smart healthcare; Smartpage, a smartphone and web-based system for hospital communication and task management to address the requirements of clinical and non-clinical users; Patientrack, a real-time patient monitoring and risk screening solution; and ExtraMed, a patient flow management software. It also provides product implementation, product support and maintenance, systems integration, and data analysis services.

Alcidion Group Fundamentals Summary

How do Alcidion Group's earnings and revenue compare to its market cap?
ALC fundamental statistics
Market CapAU$366.82m
Earnings (TTM)-AU$2.24m
Revenue (TTM)AU$25.88m

14.2x

P/S Ratio

-163.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALC income statement (TTM)
RevenueAU$25.88m
Cost of RevenueAU$3.02m
Gross ProfitAU$22.86m
ExpensesAU$25.11m
Earnings-AU$2.24m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0021
Gross Margin88.34%
Net Profit Margin-8.67%
Debt/Equity Ratio0%

How did ALC perform over the long term?

See historical performance and comparison

Valuation

Is Alcidion Group undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ALC (A$0.35) is trading below our estimate of fair value (A$0.78)

Significantly Below Fair Value: ALC is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ALC is unprofitable, so we can't compare its PE Ratio to the Global Healthcare Services industry average.

PE vs Market: ALC is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALC is overvalued based on its PB Ratio (8.1x) compared to the AU Healthcare Services industry average (3.8x).


Future Growth

How is Alcidion Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

140.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: ALC is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ALC's is expected to become profitable in the next 3 years.

Revenue vs Market: ALC's revenue (29.2% per year) is forecast to grow faster than the Australian market (5.3% per year).

High Growth Revenue: ALC's revenue (29.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ALC's Return on Equity is forecast to be low in 3 years time (13%).


Past Performance

How has Alcidion Group performed over the past 5 years?

2.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALC is currently unprofitable.

Growing Profit Margin: ALC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALC is unprofitable, but has reduced losses over the past 5 years at a rate of 2.5% per year.

Accelerating Growth: Unable to compare ALC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALC is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (39.5%).


Return on Equity

High ROE: ALC has a negative Return on Equity (-4.96%), as it is currently unprofitable.


Financial Health

How is Alcidion Group's financial position?


Financial Position Analysis

Short Term Liabilities: ALC's short term assets (A$30.3M) exceed its short term liabilities (A$13.0M).

Long Term Liabilities: ALC's short term assets (A$30.3M) exceed its long term liabilities (A$164.0K).


Debt to Equity History and Analysis

Debt Level: ALC is debt free.

Reducing Debt: ALC has no debt compared to 5 years ago when its debt to equity ratio was 0.08%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable ALC has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: ALC is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 1.6% per year.


Dividend

What is Alcidion Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALC's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Kate Quirke

3.25yrs

Tenure

AU$614,564

Compensation

Ms. Kate Quirke has been Chief Executive Officer and Executive Director of Alcidion Group Ltd. since July 3, 2018 and has been its Managing Director since January 25, 2019. Ms. Quirke served as Chief Execu...


CEO Compensation Analysis

Compensation vs Market: Kate's total compensation ($USD455.74K) is about average for companies of similar size in the Australian market ($USD551.68K).

Compensation vs Earnings: Kate's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ALC's management team is considered experienced (2.6 years average tenure).


Board Members

Experienced Board: ALC's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.8%.


Top Shareholders

Company Information

Alcidion Group Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Alcidion Group Limited
  • Ticker: ALC
  • Exchange: ASX
  • Founded: 2000
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: AU$366.824m
  • Shares outstanding: 1.05b
  • Website: https://www.alcidion.com

Location

  • Alcidion Group Limited
  • 9 Yarra Street
  • Level 10
  • South Yarra
  • Victoria
  • 3141
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/15 15:50
End of Day Share Price2021/10/15 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.